glp 1 agonist anesthesia GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus AAOMS may update anesthesia guide

May 12, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity, Practice Management, Type 2 Diabetes, Type 2 Diabetes 1,313 views A patient starts semaglutide through a telehealth platform, receives nutrition advice from a wellness clinic, and later visits a primary care physician for worsening gastrointestinal symptoms

The critical role of underlying coronary artery disease (CAD) in the pathogenesis of AF and ventricular fibrillation should not be overlooked

While the FDA recently approved the first generic version of Victoza , or liraglutidea first-generation GLP-1 that has been on the FDA's shortage list since 2023demand for the once-daily injection has waned as patients move to more effective once-weekly treatments like Ozempic and Mounjaro

10.1089/met.2012.0128 [DOI] [PubMed] [Google Scholar] 160.Maiztegui B, Borelli MI, Madrid VG, Del ZH, Raschia MA, Francini F, et al